In the last trading session, 1.14 million Kymera Therapeutics Inc (NASDAQ:KYMR) shares changed hands as the company’s beta touched 2.18. With the company’s per share price at $43.64 changed hands at -$0.48 or -1.09% during last session, the market valuation stood at $3.06B. KYMR’s last price was a discount, traded about -22.07% off its 52-week high of $53.27. The share price had its 52-week low at $19.44, which suggests the last value was 55.45% up since then. When we look at Kymera Therapeutics Inc’s average trading volume, we note the 10-day average is 1.07 million shares, with the 3-month average coming to 950.36K.
Analysts gave the Kymera Therapeutics Inc (KYMR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended KYMR as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight.
Kymera Therapeutics Inc (NASDAQ:KYMR) trade information
Instantly KYMR was in red as seen at the end of in last trading. With action -5.72%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 46.00%, with the 5-day performance at -5.72% in the red. However, in the 30-day time frame, Kymera Therapeutics Inc (NASDAQ:KYMR) is 44.26% up. Looking at the short shares, we see there were 7.58 million shares sold at short interest cover period of 7.15 days.
The consensus price target for the stock as assigned by Wall Street analysts is 59.5, meaning bulls need an upside of 26.66% from its current market value. According to analyst projections, KYMR’s forecast low is 54 with 64 as the target high. To hit the forecast high, the stock’s price needs a -46.65% plunge from its current level, while the stock would need to soar -23.74% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -26.36%. The 2025 estimates are for Kymera Therapeutics Inc earnings to decrease by -12.60%, but the outlook for the next 5-year period is at -9.96% per year.
KYMR Dividends
Kymera Therapeutics Inc is expected to release its next quarterly earnings report on 2025-May-09.
Kymera Therapeutics Inc (NASDAQ:KYMR)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.69% of Kymera Therapeutics Inc shares while 111.66% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 114.75%. There are 111.66% institutions holding the Kymera Therapeutics Inc stock share, with PRICE T ROWE ASSOCIATES INC /MD/ the top institutional holder. As of 2024-06-30, the company held 8.7472% of the shares, roughly 6.39 million KYMR shares worth $190.76 million.
BAKER BROS. ADVISORS LP holds the second largest percentage of outstanding shares, with 8.2069% or 6.0 million shares worth $178.98 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were T. Rowe Price New Horizons Fund, Inc. and VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund . With 3.05 shares estimated at $133.18 million under it, the former controlled 4.69% of total outstanding shares. On the other hand, VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund held about 3.61% of the shares, roughly 2.35 shares worth around $102.62 million.
